Prasanna Kumar Nidamarthy

No ORCID on file · 1 paper in corpus
nonrandomized-trial 2022
Clinical pharmacology in drug development ·doi:10.1002/cpdd.1052

This phase 1 postapproval study assessed the effect of the mitogen-activated protein kinase kinase enzyme 1/enzyme 2 inhibitor trametinib (2 mg once daily, repeat dosing) on the pharmacokinetics of combined oral contraceptives (COCs) contai…